As for non-enzymatic pretreatments of the intratumoral ECM, an original approach was recently described by Li et al. [102] who used a MAtrix REgulating MOtif (MAREMO)-mimicking peptide, which binds to the ECM protein tenascin-C and by so neutralizes pro-tumor activities of the latter via inhibiting interactions of tenascin-C with fibronectin, TGFβ, CXCL12, and others. The gene discussed is TGFB1; the disease is neoplasm.